Advancing Enrollment and Reducing Drug Costs Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Advancing Enrollment and Reducing Drug Costs Act of 2023 is a House bill introduced in the 118th Congress aimed at improving enrollment processes and lowering prescription drug costs. The bill is categorized under the health policy area and was referred to the Subcommittee on Health as of December 17, 2024. However, the bill has failed or expired and no full text or official summary is publicly available, limiting detailed analysis.
This bill sought to address enrollment and drug cost issues in health care but did not advance beyond subcommittee referral and ultimately failed or expired in the 118th Congress.
- The bill is titled 'Advancing Enrollment and Reducing Drug Costs Act of 2023' and was introduced in the House of Representatives.
- It was referred to the Subcommittee on Health on December 17, 2024, indicating initial committee consideration.
- The bill status is marked as failed or expired, meaning it did not become law during the 118th Congress.
['Potential beneficiaries could include patients seeking lower prescription drug costs and individuals needing improved enrollment processes in health programs, though specifics are unavailable due to missing bill text.', 'Health agencies and organizations involved in enrollment and drug cost management might also be affected.']
['Lack of publicly available full bill text and official summary limits understanding of implementation details and cost implications.', 'Without detailed provisions, it is unclear what authority or oversight mechanisms the bill would establish or modify.', 'The failure or expiration of the bill indicates potential challenges in legislative support or policy consensus.']
The bill was introduced during the 118th Congress and referred to a relevant subcommittee but did not progress further. The absence of a summary or full text in public records restricts insight into legislative debates or stakeholder positions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced enrollment efficiency and drug pricing structures, potentially affecting healthcare providers and pharmaceutical markets.', 'Failure to pass may maintain current enrollment and drug cost frameworks without reform.']
The absence of an official summary and full bill text restricts transparency and public understanding of the bill's intended provisions and impacts. Monitoring legislative progress and ensuring availability of complete documentation are essential for effective government transparency and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.